For this, we explored the possibility that the beneficial actions of GLP-1/GIP dual agonism in the liver of animals [28] and patients [12, 17] with MASH could be exerted through actions within two of the most relevant cell populations involved in the progression of liver fibrosis: hepatocytes and HSCs. Here, GIP is linked to Hepatic fibrosis.